- Home
- QCRH vs IOVA Comparison
QCRH vs IOVA Comparison
Compare QCRH & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- IOVA
- Stock Information
- Founded
- QCRH 1993
- IOVA 2007
- Country
- QCRH United States
- IOVA United States
- Employees
- QCRH N/A
- IOVA N/A
- Industry
- QCRH Major Banks
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QCRH Finance
- IOVA Health Care
- Exchange
- QCRH Nasdaq
- IOVA Nasdaq
- Market Cap
- QCRH 1.2B
- IOVA 975.1M
- IPO Year
- QCRH 1993
- IOVA N/A
- Fundamental
- Price
- QCRH $78.96
- IOVA $2.69
- Analyst Decision
- QCRH Buy
- IOVA Buy
- Analyst Count
- QCRH 3
- IOVA 11
- Target Price
- QCRH $88.83
- IOVA $11.90
- AVG Volume (30 Days)
- QCRH 99.6K
- IOVA 16.7M
- Earning Date
- QCRH 07-23-2025
- IOVA 08-07-2025
- Dividend Yield
- QCRH 0.31%
- IOVA N/A
- EPS Growth
- QCRH N/A
- IOVA N/A
- EPS
- QCRH 6.63
- IOVA N/A
- Revenue
- QCRH $322,873,000.00
- IOVA $241,525,000.00
- Revenue This Year
- QCRH N/A
- IOVA $86.62
- Revenue Next Year
- QCRH $7.11
- IOVA $69.13
- P/E Ratio
- QCRH $11.85
- IOVA N/A
- Revenue Growth
- QCRH N/A
- IOVA 636.99
- 52 Week Low
- QCRH $60.83
- IOVA $1.64
- 52 Week High
- QCRH $96.08
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- QCRH 70.85
- IOVA 54.92
- Support Level
- QCRH $74.50
- IOVA $2.44
- Resistance Level
- QCRH $76.17
- IOVA $2.85
- Average True Range (ATR)
- QCRH 1.52
- IOVA 0.24
- MACD
- QCRH 0.44
- IOVA -0.00
- Stochastic Oscillator
- QCRH 98.81
- IOVA 83.16
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.